|
Nov 29
|
Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights
|
|
Nov 27
|
Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases
|
|
Nov 7
|
Ceapro Inc. Enters into Technical Collaboration with NATEX Prozesstechnologie GmbH and Provides Update on the Scale-Up Project for its Patented Pressurized Gas eXpanded (PGX) Technology
|